|
| | SR0737 | | LRB103 39201 MST 69348 r |
|
|
| 1 | | SENATE RESOLUTION |
| 2 | | WHEREAS, Cholangiocarcinoma (bile duct cancer) is a rare |
| 3 | | form of cancer that originates from the cells lining the bile |
| 4 | | ducts that play a key role in digestion; there are three types |
| 5 | | of this cancer, intrahepatic, extrahepatic, and perihilar; and |
| 6 | | WHEREAS, Approximately 12,000 Americans are diagnosed each |
| 7 | | year with cholangiocarcinoma, with numbers increasing yearly, |
| 8 | | and the mortality rate has increased dramatically in the last |
| 9 | | decade; and |
| 10 | | WHEREAS, Patients are typically diagnosed at a late stage |
| 11 | | due to the lack of a validated early method of detection; |
| 12 | | symptoms of jaundice, abdominal pain, itchy skin, and weight |
| 13 | | loss are symptoms that do not usually present until advanced |
| 14 | | disease progression; and |
| 15 | | WHEREAS, Cholangiocarcinoma is a rare cancer; of the top |
| 16 | | eight deadliest cancers, seven are rare; rare cancers have a |
| 17 | | five-year survival rate under 50%, with the cholangiocarcinoma |
| 18 | | five-year survival rate being approximately 20%; and |
| 19 | | WHEREAS, There is currently no cure for |
| 20 | | cholangiocarcinoma/bile duct cancer; and |